Market Alert: Ukraine Conflict Update and U.S. Policy Risk
MedAdvisor Solutions (ASX: MDR) has reported FY25 results, with revenue from continuing operations down 36% to AU$63.0 million, impacted by weaker performance in its US programs. Gross profit fell to AU$32.9 million, while EBITDA before impairment recorded an AU$10.7 million loss. An AU$46.5 million impairment charge pushed NPAT to an AU$63.3 million loss. The Company successfully raised AU$7.7 million and advanced its Transformation 360° program, achieving over 70% completion of the US platform build. Post year-end, MedAdvisor sold its ANZ business to Jonas Software for AU$35 million plus up to AU$7.35 million in earn-outs, leaving the group debt-free with AU$16.5 million net cash.
FY26 revenue guidance has been withdrawn due to short-term uncertainty, though cost-out targets and the US pipeline remain intact. CEO Rick Ratliff confirmed the Company’s focus is now firmly on strengthening and scaling its US business while reviewing strategic options.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Aug 29, 2025
Aug 29, 2025
Aug 29, 2025
Aug 29, 2025
Aug 29, 2025
Aug 29, 2025
Aug 29, 2025
Aug 29, 2025
Aug 28, 2025
Aug 28, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.